Loading…
TLSA
Tiziana Life Sciences Ltd
NASDAQ· Healthcare· Biotechnology· CUSIP G88912103
$1.01-6.48%Price as of Aug 29, 18:41 UTC · updated once a day, after the close
Key metrics
- Market cap
- $128.53M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.16
- ROE
- -924.32%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.46
- 52-week high
- $2.35
- 52-week low
- $0.87
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -35.3% over 5Y.
today you would have $691.78▼ -30.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.49 | $0.70 | $0.56 | $0.60 | |
| P/B | 15.0x | 3453.0x | 19.8x | 10.3x | 3.1x |
| EPS | -$0.16 | -$0.11 | -$0.17 | -$0.15 | |
| ROE | -310.48% | -35444.23% | -301.40% | -319.56% | -78.67% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| VANIVivani Medical, Inc. | $1.42 | — | 6.7x | — | -220.41% | $128.09M |
| MXCTMaxcyte Inc | $1.24 | — | 0.8x | — | -20.39% | $127.98M |
| VTVTvTv Therapeutics Inc. | $32.36 | — | 5.1x | — | -15.80% | $127.95M |
| BDTXBlack Diamond Therapeutics, Inc. | $2.23 |
About the company
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
- 10
- London, United Kingdom
Company description provided by Yahoo Finance.